Skip to main content
Fig. 1 | The Journal of Headache and Pain

Fig. 1

From: Real-world effectiveness of fremanezumab in migraine patients initiating treatment in the United States: results from a retrospective chart study

Fig. 1

Study design and dosing for patients with migraine. EM, episodic migraine; CM, chronic migraine; MMD, monthly migraine days; MHD, monthly headache days; HIT-6, 6-item Headache Impact Test; MIDAS, Migraine Disability Assessment. aMigraine diagnosis could have been established before 12 months pre-index, but data were extracted as close to fremanezumab initiation as possible. bBaseline patient information (eg, comorbidities, prior treatments) were collected over 12 months pre-index, while baseline clinical outcomes (eg, MMD, MHD, HIT-6, MIDAS) were collected during the 3 months pre-index

Back to article page

The Journal of Headache and Pain

ISSN: 1129-2377

Contact us